Neal I Lindeman

Neal I Lindeman

UNVERIFIED PROFILE

Are you Neal I Lindeman?   Register this Author

Register author
Neal I Lindeman

Neal I Lindeman

Publications by authors named "Neal I Lindeman"

Are you Neal I Lindeman?   Register this Author

97Publications

3348Reads

10Profile Views

Proficiency Testing of Standardized Samples Shows High Interlaboratory Agreement for Clinical Next Generation Sequencing-Based Hematologic Malignancy Assays With Survey Material-Specific Differences in Variant Frequencies.

Arch Pathol Lab Med 2020 Jan 27. Epub 2020 Jan 27.

From the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Drs Keegan, Lindeman, and Kim); the Departments of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); Biostatistics (Mr Long) and Proficiency Testing (Ms Vasalos), ollege of American Pathologists, Northfield, Illinois; the UNC Lineberger Comprehensive Cancer Center (Dr Merker) and the Department of Pathology and Laboratory Medicine (Dr Montgomery), University of North Carolina, Chapel Hill; the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, PierianDx, St Louis, Missouri (Dr Nagarajan); the Department of Pathology and Laboratory Medicine, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, New York (Dr Rothberg); the Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas (Dr Routbort); and the Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland (Dr Xian).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2019-0352-CPDOI Listing
January 2020

Morphologic, Immunohistochemical, and Molecular Distinction Between Fibroepithelioma of Pinkus and "Fenestrated" Basal Cell Carcinoma.

Am J Dermatopathol 2019 Nov 5. Epub 2019 Nov 5.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001563DOI Listing
November 2019

Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the , , and Genes: A Study of the College of American Pathologists Molecular Oncology Committee.

Arch Pathol Lab Med 2019 Oct 10;143(10):1203-1211. Epub 2019 Apr 10.

From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr Kamel-Reid); the Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston (Dr Lazar); the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Drs Lindeman and Kim); Biostatistics (Mr Long) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill (Dr Merker); the Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York (Dr Rai); the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); and the Department of Pathology and Laboratory Medicine, Strong Memorial Hospital, University of Rochester Medical Center and Pathology and Laboratory Medicine, Molecular Diagnostic Laboratory, Rochester, New York (Dr Rothberg). Dr Moncur is employed by the US Army. The identification of specific products or scientific instrumentation is considered an integral part of the scientific endeavor and does not constitute endorsement or implied endorsement on the part of the authors, the Department of Defense, or any component agency. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, Department of Defense, or US government. The other authors have no relevant financial interest in the products or companies described in this article.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0396-CPDOI Listing
October 2019

-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.

Gynecol Oncol Rep 2019 May 29;28:15-17. Epub 2019 Jan 29.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525789193001
Publisher Site
http://dx.doi.org/10.1016/j.gore.2019.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357694PMC
May 2019

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Arch Pathol Lab Med 2019 04 30;143(4):463-471. Epub 2018 Oct 30.

From the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); the Departments of Pathology (Drs Devereaux and Montgomery, and Mr Smail) and Genetics (Dr Montgomery), Stanford University School of Medicine, and the Biomedical Informatics Program (Mr Smail), Stanford University, Stanford, California; the Department of Pathology, Massachusetts General Hospital (Dr Iafrate), and the Department of Pathology, Brigham and Women's Hospital (Drs Kim and Lindeman), Harvard University, Boston; the Departments of Pathology and Clinical Laboratory Genetics, The University Health Network and the University of Toronto, Toronto, Ontario, Canada (Dr Kamel-Reid); the Department of Pathology, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Moncur); PierianDx, St Louis, Missouri (Dr Nagarajan); the Department of Global Medical Affairs, Roche, Tucson, Arizona (Dr Portier); the Departments of Hematopathology (Dr Routbort) and Pathology, Genomic Medicine, and Translational Molecular Pathology (Dr Lazar), he University of Texas MD Anderson Cancer Center, Houston (Dr Routbort); the Department of Pathology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia (Dr Surrey); and Proficiency Testing, College of American Pathologists, Northfield, Illinois (Ms Vasalos).

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2018-033
Publisher Site
http://dx.doi.org/10.5858/arpa.2018-0336-CPDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910717PMC
April 2019

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.

Mod Pathol 2018 12 28;31(12):1882-1890. Epub 2018 Jun 28.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-018-0091-xDOI Listing
December 2018

Targeted Next-Generation Sequencing Reveals Clinically Actionable and Mutations in Low-Grade Serous Ovarian Carcinoma.

JCO Precis Oncol 2018 8;2018. Epub 2018 Nov 8.

Elizabeth H. Stover, Ursula A. Matulonis, and Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School; and Colleen Feltmate, Ross S. Berkowitz, and Neal I. Lindeman, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394870PMC
November 2018

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.

Gynecol Oncol 2018 08 22;150(2):219-226. Epub 2018 Jun 22.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.05.028DOI Listing
August 2018

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Arch Pathol Lab Med 2018 Mar 22;142(3):321-346. Epub 2018 Jan 22.

From the Departments of Pathology (Drs Lindeman and Sholl) and Medicine (Dr Kwiatkowski), Brigham and Women's Hospital, Boston, Massachusetts; the Cancer Center (Dr Bernicker) and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Pathology, University of Colorado School of Medicine, Denver (Dr Aisner); the Diagnostic and Molecular Pathology Laboratory (Dr Arcila) and the Molecular Diagnostics Service (Dr Ladanyi), Memorial Sloan Kettering Cancer Center, New York, New York; the Department of Pathology & Medicine, Pulmonary, Critical Care and Sleep Medicine, New York, New York (Dr Beasley); the Pathology and Laboratory Quality Center, College of American Pathologists, Northfield, Illinois (Mss Colasacco and Ventura); the Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (Dr Dacic); the Department of Medicine and Pathology, University of Colorado, Denver (Dr Hirsch); the Department of Pathology, University of Aberdeen, Aberdeen, Scotland (Dr Kerr); the Department of Molecular Pathology, Roswell Park Cancer Institute, Buffalo, New York (Dr Nowak); the Clinical and Scientific Affairs Division, Association for Molecular Pathology, Bethesda, Maryland (Dr Temple-Smolkin); the Molecular Therapeutics and Biomarkers Laboratory, Peter Maccallum Cancer Center, Melbourne, Australia (Dr Solomon); the Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands (Dr Thunnissen); the Department of Laboratory Medicine and Pathobiology, Princess Margaret Cancer Center, Toronto, Ontario, Canada (Dr Tsao); Scientific Affairs, International Association for the Study of Lung Cancer, Aurora, Colorado (Dr Wynes); and the Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan (Dr Yatabe). Dr Souter is in private practice in Wellanport, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0388-CPDOI Listing
March 2018

Authors' Reply.

J Mol Diagn 2018 01;20(1):125-126

Interpretation of Sequence Variants in Somatic Conditions Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Bethesda, Maryland; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2017.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818630PMC
January 2018

Somatic mutations in and in primary carcinomas at 13 anatomic sites.

Oncotarget 2017 Oct 21;8(49):85680-85691. Epub 2017 Sep 21.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/21115
Publisher Site
http://dx.doi.org/10.18632/oncotarget.21115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689640PMC
October 2017

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Neuro Oncol 2017 Jul;19(7):986-996

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Department of Pathology, Department of Radiology, Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts; Department of Medical Oncology, Oncologic Pathology, Department of Pediatric Oncology, Department of Cancer Biology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Pathology, Department of Neurosurgery, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Pratiti Bandopadhayay, Broad Institute of MIT and Harvard, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570190PMC
July 2017

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Neuro Oncol 2017 Jul;19(7):908-917

Department of Radiation Oncology, Department of Pathology, Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center (DF/BWCC), Harvard Medical School, Boston, Massachusetts; Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Accelerate Brain Cancer Cure (ABC2), Washington, DC; Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now312DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570228PMC
July 2017

The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.

Blood 2017 07 9;130(4):433-439. Epub 2017 Jun 9.

Department of Pathology, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-03-734533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813726PMC
July 2017

Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.

Arch Pathol Lab Med 2017 Jun 3;141(6):751-758. Epub 2017 Mar 3.

From the Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital (Drs Garcia, Minkovsky, Jia, Ligon, Sholl, Kuo, MacConaill, Lindeman, and Dong, Messrs Ducar and Gong, and Ms. Shivdasani), and the Center for Cancer Genome Discovery, Dana Farber Cancer Institute (Mr Ducar and Dr MacConaill), Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2016-0527-OADOI Listing
June 2017

PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.

Appl Immunohistochem Mol Morphol 2016 May-Jun;24(5):313-9

Department of Pathology, Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000195DOI Listing
May 2017

Reporting Results of Molecular Tests: A Retrospective Examination of BRAF Mutation Reporting.

Arch Pathol Lab Med 2017 May 13;141(5):658-665. Epub 2017 Mar 13.

From the Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora (Dr Treece); the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill (Dr Gulley); College of American Pathologists, Northfield, Illinois (Ms Vasalos); the Department of Pathology, Warren Alpert Medical School of Brown University, Providence, Rhode Island (Dr Paquette); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Lindeman); the Department of Pathology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr Jennings); and the Department of Pathology and Laboratory Medicine, St. Joseph Mercy Hospital, Ann Arbor, Michigan (Dr Bartley).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2016-0280-CPDOI Listing
May 2017

Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology.

J Clin Oncol 2017 Mar 13;35(9):929-933. Epub 2017 Feb 13.

Yuri Sheikine, Beth Israel Deaconess Medical Center, Harvard Medical School; and Frank C. Kuo and Neal I. Lindeman, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7539DOI Listing
March 2017

Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.

J Clin Endocrinol Metab 2016 12 30;101(12):4938-4944. Epub 2016 Sep 30.

Thyroid Section, Division of Endocrinology, Hypertension, and Diabetes (S.K., T.E.A., N.K., C.A.A., E.M., M.I.K., P.R.L., E.K.A.), and Departments of Radiology (H.T.H., M.C.F., C.B.B.), Pathology (E.S.C., J.F.K., J.A.B., N.I.L.), and Surgery (A.A.G., N.L.C., M.N., F.D.M.), The Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2016-2620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155682PMC
December 2016

The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR.

J Mol Diagn 2016 11 15;18(6):864-871. Epub 2016 Sep 15.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2016.06.009DOI Listing
November 2016

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.

J Mol Diagn 2016 07;18(4):507-15

Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2016.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707186PMC
July 2016

Molecular testing of different cytologic preparations in patients with advanced lung adenocarcinoma: which yields the best results?

J Am Soc Cytopathol 2017 Jan - Feb;6(1):16-23. Epub 2016 Jun 17.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jasc.2016.06.002DOI Listing
June 2016

Evaluation for High-risk HPV in Squamous Cell Carcinomas and Precursor Lesions Arising in the Conjunctiva and Lacrimal Sac.

Am J Surg Pathol 2016 Apr;40(4):519-28

*Pathology Service, Massachusetts General Hospital ‡Department of Ophthalmology, David G. Cogan Laboratory of Ophthalmic Pathology, Massachusetts Eye and Ear Infirmary §Department of Otolaryngology, Massachusetts Eye and Ear Infirmary #Department of Pathology, Brigham and Women's Hospital †Harvard Medical School, Boston, MA ∥Department of Ophthalmology, L.F. Montgomery Laboratory of Ophthalmic Pathology, Emory University, Atlanta, GA ¶Division of Head and Neck Oncologic Surgery, The Ohio State Wexner Medical Center, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000581DOI Listing
April 2016

KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.

J Thorac Oncol 2016 Apr 30;11(4):496-503. Epub 2016 Jan 30.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.01.010DOI Listing
April 2016

Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-κB regulatory genes.

Mod Pathol 2016 Jan 13;29(1):67-74. Epub 2015 Nov 13.

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2015.130DOI Listing
January 2016

Training the Future Leaders in Personalized Medicine.

J Pers Med 2016 Jan 7;6(1). Epub 2016 Jan 7.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jpm6010001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810380PMC
January 2016

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.

Neuro Oncol 2015 Oct 9;17(10):1344-55. Epub 2015 Mar 9.

Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.H.R., L.A.R., S.H., D.K., Y.J.K., K.L.L.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.E.S., L.B., M.B., D.A.R., E.Q.L., M.L.R., A.D.N., L.N., S.R., L.M.D., D.C.L., P.K., B.J.R., P.Y.W., R.B., K.L.L.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B., E.B.C, O.A.-M., M.D.J., A.J.G., I.F.D., E.A.C.); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (M.H., A.A.A., N.D.A., B.M.A.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (M.H., A.A.A., N.D.A., B.M.A.); Harvard Radiation Oncology Program, Boston, Massachusetts (A.R.); Kravis Center for Molecular Oncology & Department of Epidemiology and Biostatistics, Memorial Sloan- Kettering Cancer Center, New York, New York (N.S.); Broad Institute, Cambridge, Massachusetts (R.B.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., A.D., J.B.C., M.A., S.S., R.D.F., N.I.L., A.H.L., K.L.L.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578577PMC
October 2015

Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.

JAMA Oncol 2015 Oct;1(7):879-80

Havard Medical School, Boston, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1540DOI Listing
October 2015

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing.

Exp Hematol Oncol 2015 8;4:30. Epub 2015 Oct 8.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-015-0026-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599757PMC
October 2015

The Cancer Genomics Resource List 2014.

Arch Pathol Lab Med 2015 Aug 1;139(8):989-1008. Epub 2014 Dec 1.

From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee (Dr Zutter); the Department of Pathology, Clarient Diagnostic Services, Aliso Viejo, California (Dr Bloom); the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis (Dr Cheng); the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Drs Hagemann and Pfeifer); Surveys, College of American Pathologists, Northfield, Illinois (Dr Kaufman); the Department of Pathology, Emory University, Atlanta, Georgia (Dr Krasinskas); the Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston (Dr Lazar); the Department of Pathology and Laboratory Medicine, Fletcher Allen Health Care, Burlington, Vermont (Dr Leonard); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Lindeman); the Department of Pathology, Mayo Clinic, Rochester, Minnesota (Dr Moyer); Molecular and Genomic Pathology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Nikiforova); the Department of Pathology, NorthShore University Health System, Evanston, Illinois (Dr Nowak); the Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York (Dr Sepulveda); the Department of Pathology, Case Medical Center/Case Western Reserve University, Cleveland, Ohio (Dr Willis); and the Department of Molecular Pathology and Hematopathology, University of Minnesota, Minneapolis (Dr Yohe).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2014-0330-CPDOI Listing
August 2015

Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.

J Thorac Oncol 2015 Apr;10(4):586-94

*Institute for Technology Assessment, Massachusetts General Hospital, Harvard University, Boston, Massachusetts; †Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; ‡Department of Economics, Harvard University, Cambridge, Massachusetts; §Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts; ‖Department of Pathology, Brigham and Women' Hospital, Harvard Medical School, Boston, Massachusetts; and ¶Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395466PMC
April 2015

BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers.

Nucleic Acids Res 2015 Feb 26;43(3):e19. Epub 2014 Nov 26.

Center for Cancer Genome Discovery and Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gku1211DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330340PMC
February 2015

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.

Clin Cancer Res 2014 Dec 7;20(24):6551-8. Epub 2014 Oct 7.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1337DOI Listing
December 2014

Identification of a melanoma susceptibility locus and somatic mutation in TET2.

Carcinogenesis 2014 Sep 30;35(9):2097-101. Epub 2014 Jun 30.

Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA, Channing Division of Network Medicine and Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN 46202, USA, Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA and Department of Dermatology, School of Medicine, Indiana University, Indianapolis, IN 46202, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgu140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146422PMC
September 2014

Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.

Arch Pathol Lab Med 2014 Feb 28;138(2):171-4. Epub 2013 Jun 28.

From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Drs Sholl and Lindeman); the Department of Laboratory Medicine, Grand River Hospital, Kitchener, Ontario, Canada (Dr Divaris); the Department of Pathology, James A. Haley Veterans' Hospital, Tampa, Florida (Dr Foulis); the Cancer Information Program, Cancer Care Ontario, Ontario, Canada (Ms Lee); the Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford, California (Dr Neal); the Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois (Dr Nowak); and the Department of Hematology-Oncology, Palo Alto Medical Foundation, Mountain View, California (Dr Yu). Dr Alsabeh is in private practice, Beverly Hills, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2013-0232-CPDOI Listing
February 2014

Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Am J Surg Pathol 2014 Feb;38(2):279-88

*Massachusetts General Hospital †Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000140DOI Listing
February 2014

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

An improved algorithm for activated protein C resistance and factor V Leiden screening.

Am J Clin Pathol 2013 Sep;140(3):379-86

Department of Pathology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1309/AJCPO6VUP3MZEYWUDOI Listing
September 2013

Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.

Clin Chem Lab Med 2013 May;51(5):1053-7

Department of Pathology, Center for Advanced Molecular Diagnostics, Brigham and Women’s Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2012-0300DOI Listing
May 2013

Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia.

Clin Lymphoma Myeloma Leuk 2013 Apr;13(2):247-9

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.03.001DOI Listing
April 2013

Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.

Clin Lymphoma Myeloma Leuk 2013 Apr;13(2):250-2

Bing Center for Waldenström's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.04.002DOI Listing
April 2013

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(12):1767-1774

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182745bcbDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500523PMC
December 2012

Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.

J Mol Diagn 2010 Mar 21;12(2):177-83. Epub 2010 Jan 21.

Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 44 Binney St., Room JF-215C, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2353/jmoldx.2010.090106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871724PMC
March 2010

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.

Cancer 2009 Feb;117(1):67-72

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncy.20011
Publisher Site
http://dx.doi.org/10.1002/cncy.20011DOI Listing
February 2009

Intravascular cytotoxic T-cell lymphoma: A case report and review of the literature.

J Am Acad Dermatol 2008 Feb;58(2):290-4

Department Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2006.12.022DOI Listing
February 2008

Selecting automation for the clinical chemistry laboratory.

Arch Pathol Lab Med 2007 Jul;131(7):1063-9

Department of Pathology, Division of Clinical Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1043/1543-2165(2007)131[1063:SAFTCC]2.0.CO;2DOI Listing
July 2007

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Clin Cancer Res 2006 Jul;12(14 Pt 2):4403s-4408s

Cancer Center and Department of Medicine, Massachusetts General Hospital, and Laboratory for Molecular Medicine, Harvard Medical School, Boston 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0099DOI Listing
July 2006

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

J Clin Oncol 2005 Oct 19;23(28):6976-81. Epub 2005 Sep 19.

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.4182DOI Listing
October 2005